Enhancing AAV6 Vector Production For Cell Therapies: Harnessing The Potential Of Pro10™ Platform For Scalable Manufacturing

By Maria Iglesias, Ana Barbas, and César Trigueros

The field of cell and gene therapy holds immense promise for tackling a vast array of diseases, from genetic disorders to cancer. To unlock this potential fully, efficient and targeted delivery of therapeutic genes or factors into cells is crucial. Viral vectors are the workhorses for both cell and gene therapies, with lentivirus and retrovirus traditionally favored for cell therapies and Adeno-associated virus (AAV) vectors dominating gene therapies. However, AAV vectors are increasingly seen as having exciting potential in cell therapy due to their ability to target a broad range of cell types. AAV6, in particular, stands out as a serotype of choice for various cell therapy approaches. Its broad tropism, high transduction efficiency in many cell types, enhanced targeting of muscle tissue, low pre-existing immunity, and favorable safety profile make it a highly advantageous candidate.

For robust manufacturing of AAV6 vectors, Viralgen's Pro10™ production platform offers proven reliability and scalability, making it ideal for meeting the demands of large-scale cell therapy production. The Pro10™ platform boasts a well-established process that consistently yields high-quality AAV6 vectors, ensuring a reliable supply that scales to meet cGMP requirements. Viralgen's extensive experience with AAV6 production further highlights their commitment to excellence in this field. They have successfully manufactured 9 batches for toxicological studies, over 100 2L batches, and a substantial number of cGMP batches (250/500 L cell culture), demonstrating continuous advancement and a focus on high-quality production. Importantly, run data across these batches, despite variations in the Gene of Interest (GOI) within the AAV6 constructs, showcase consistency and robustness. This confirms the efficacy of the Pro10™ platform in reliably producing AAVs for advancing cell therapies.